Superiority of SPECT/CT over planar123I-mIBG images in neuroblastoma patients with impact on curie and SIOPEN score values;Überlegenheit der SPECT/CT gegenüber planaren123I-MIBG-aufnahmen bei neuroblastom-patienten mit auswirkungen auf die curie-und SIOPEN scores

NuklearMedizin

Volumn 55, Issue 4, 2016, Pages 151-157

  Cerný, Igor ^a   Prášek, Jiri ^a   Kašpárková, Helena ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

123I MIBG scintigraphy; 123I MIBG semiquantitative scoring; Curie scoring; Neuroblastoma; SIOPEN scoring

Indexed keywords

ARTICLE; BONE SCINTISCANNING; CHILD; CLINICAL ARTICLE; CURIE SCORE; FEMALE; FETUS; HUMAN; INFANT; MALE; NEUROBLASTOMA; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSTIC ASSESSMENT; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SIOPEN SCORE; CANCER STAGING; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EVALUATION STUDY; IMAGE ENHANCEMENT; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY;

(3 IODOBENZYL)GUANIDINE; RADIOPHARMACEUTICAL AGENT;

3-IODOBENZYLGUANIDINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMAGE ENHANCEMENT; INFANT; INFANT, NEWBORN; MALE; NEOPLASM STAGING; NEUROBLASTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY;

EID: 84982903057     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0743-15-05     Document Type: Article

References (28)

1. 123I-MIBG whole body scan scoring method – Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31: 256–261.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nature Rev Cancer 2003; 3: 203–216.
3. Decarolis B, Schneider C, Hero B et al. Iodine-123 Metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: Results of the Cologne Interscore Comparison Study. J Clin Oncol 2013; 31: 944–951.
4. DuBois SG, Kalika Y, Lukens JN et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediat Hematol Oncol 1999; 21: 181–189.
5. Frappaz D, Bonneu A, Chauvot PC et al. Metaiodobenzylguanidine assessment of metastatic neuro - blastoma: Observer dependency and chemosensitivity evaluation. Med Pediat Oncol 2000; 34: 237–241.
6. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med 2011; 36: 1–7.
7. Gelfand MJ, Elgazzar AH, Kriss VM et al. Iodine- 123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994; 35: 1753–1757.
8. 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004; 22: 3909–3915.
9. Kushner BH, Yeh SDJ, Kramer K et al. Impact of metaiodobenzylguanidinescintigraphy on assessing response of high-risk neuroblastoma to dose- intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082–1086.
10. Lewington V, Bar Sever Z, Giammarile F et al. Development of a semi-quantitative I-123 mIBG reporting method in high risk neuroblastoma. Society of Nuclear Medicine Annual Meeting Abstracts 2009; 50 (Suppl 2): 1379.
11. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106–2120.
12. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21: 2486–2491.
13. 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102: 1319–1326.
14. Mazánek P, Bajciová V, Šterba J et al. Advances in neuroblastoma diagnostics and treatment. Onkológia 2008; 4: 257–261.
15. Messina JA, Cheng S-C, Franc BL et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediat Blood Cancer 2006; 47: 865–874.
16. Mhiri A, Slim I, Elbez I et al. The role of MIBG SPECT/CT in children with neuroblastoma compared to planar images. Eur J Nucl Med Mol Imaging 2013; 40: S310.
17. Nakajo M, Shapiro B, Copp J et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 1983; 24: 672–682.
18. 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2011; 56: 1041–1045.
19. Perel YMD, Conway JMD, Kletzel MMD et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol 1999; 21: 13–18.
20. Philip T, Helson L, Bernard J-L et al. Definition of response and remission in children over one year of age with advanced neuroblastoma: Proposition for a scoring system. Pediatr Hematol Oncol 1987; 4: 25–31.
21. 123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995; 39 (4 Suppl 1): 25–28.
22. 123I-MIBG estimation method compared with scoring system in follow-up of advanced neuroblastoma: utility of total MIBG retention ratio versus scoring method. Ann Nucl Med 2012; 26: 462–470.
23. Suc A, Lumbroso J, Rubie H et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996; 77: 805–811.
24. 131I-MIBG. J Nucl Med 2001; 42: 237–247.
25. 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52: 784–790.
26. 123I-MIBG SPECT/CT for a higher interpretation confidence in neuroblastoma. Eur J Nucl Med Mol Imaging 2013; 40: S382.
27. Yanik GA, Naranjo A, Parisi MT et al. Validation of postinduction Curie scores in high-risk neuroblastoma. J Clin Oncol 2014; 32 (Suppl): 5s (abstr 10031).
28. Yanik GA, Parisi MT, Shulkin BL et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the Children’s Oncology Group. J Nucl Med 2013; 54: 541–548.